QuatRx Pharmaceuticals

Developing therapeutics for under-served endocrine and metabolic diseases

QuatRx is focused on development of therapeutics for endocrine and metabolic diseases. The company's lead product Osphena, a selective estrogen receptor modulator, was approved by the FDA in 2013 to treat dyspareunia. Q

Status
Acquired by Shionogi in 2017
Year of Investment
2000
Strategy
Life Sciences
Location
Ann Arbor, Michigan
Frazier Team